Targeted Drug Delivery and Penetration Into Solid Tumors
Targeted Drug Delivery and Penetration Into Solid Tumors
复制标题
靶向给药和穿透实体瘤
DOI：
10.1002/med.20238
复制
发表时间：
2012-09-01
影响因子：
13.3
通讯作者：
Pasqualini, Renata
中科院分区：
文献类型：
--
作者：
Corti, Angelo;Pastorino, Fabio;Pasqualini, Renata
化疗药物向肿瘤的递送和渗透受到与肿瘤组织中异常脉管系统和改变的基质组成相关的许多因素的限制。将化疗药物与肿瘤脉管系统归巢肽偶联或将药物与影响肿瘤脉管系统内皮衬里完整性的生物制剂联合给药是改善肿瘤细胞药物递送的一种有吸引力的策略。实现这一目标的有希望的方法是基于使用含天冬氨酸-甘氨酸-精氨酸（NGR）的肽作为药物输送的配体和NGR-TNF，这是一种肽-肿瘤坏死因子-一种选择性改变药物渗透屏障的融合蛋白，目前正在恶性胸膜间皮瘤患者的随机III期试验中进行测试。
Delivery and penetration of chemotherapeutic drugs into tumors are limited by a number of factors related to abnormal vasculature and altered stroma composition in neoplastic tissues. Coupling of chemotherapeutic drugs with tumor vasculature-homing peptides or administration of drugs in combination with biological agents that affect the integrity of the endothelial lining of tumor vasculature is an appealing strategy to improve drug delivery to tumor cells. Promising approaches to achieve this goal are based on the use of Asn-Gly-Arg (NGR)-containing peptides as ligands for drug delivery and of NGR-TNF, a peptide-tumor necrosis factor-a fusion protein that selectively alters drug penetration barriers and that is currently tested in a randomized Phase III trial in patients with malignant pleural mesothelioma.